Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib in second-line esophageal and gastric junction cancer
NCT03285906Phase 3Unknown
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Mar 2017
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of Rivoceranib in esophageal cancer, esophagogastric junction cancer, sponsored by Tianjin Medical University Cancer Institute and Hospital. Status: unknown.
02
Drugs
Rivoceranib
03
Conditions
esophageal canceresophagogastric junction cancer
Beyond the preview
Go deeper on NCT03285906.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03285906.